{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:22:54Z","timestamp":1781184174088,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471769, 82103306"],"award-info":[{"award-number":["82471769, 82103306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203518"],"award-info":[{"award-number":["82203518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xiangshan Talent Project of Zhuhai People's Hospital"},{"name":"Guizhou Provincial Basic Research Program (Natural Science)"},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022B1515020010"],"award-info":[{"award-number":["2022B1515020010"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint blockade (ICB) therapy is one of the cornerstones of cancer treatment regimens, but the overall response rates remain low because of suppressive immune cells, such as myeloid-derived suppressor cells (MDSC). Therefore, it is unmet need to target MDSC to achieve better outcomes of ICB therapy. Inositol-requiring enzyme 1\u03b1 (IRE1\u03b1) is identified as a key regulator for the generation of MDSC. Here, we evaluated the potential of KIRA6, an inhibitor for IRE\u03b1 kinase activity and RNase activity, to abrogate MDSC-mediated immune suppression. KIRA6 significantly suppressed 4T1 tumor growth, decreased MDSC population and enhanced T cell infiltration. Two dosages of KIRA6 treatment directly inhibited extramedullary myelopoiesis and MDSC generation in vivo. KIRA6 abrogated the induction of MDSC from bone marrow cells and abolished the immunosuppressive capability of MDSC in vitro. Meanwhile, KIRA6 not only attenuated G-CSF production from tumor cells thereby blocking the induction of MDSC, but also caused apoptosis of tumor cells. Moreover, KIRA6 treatment diminished MDSC generation, restored T cell proportion in both local and systemic immune landscapes and eventually overcame resistance to anti-PD-1 therapy. Our work establishes the evidence for KIRA6 as an impressive agent for abrogating MDSC-mediated immune suppression, killing tumor, and overcoming ICB resistance.<\/jats:p>","DOI":"10.1038\/s41419-025-08401-6","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T17:05:18Z","timestamp":1766855118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-0478","authenticated-orcid":false,"given":"Ya","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2603-642X","authenticated-orcid":false,"given":"Meixiao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8598-4824","authenticated-orcid":false,"given":"Yongjun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-2064","authenticated-orcid":false,"given":"Hong-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"8401_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"8401_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"8401_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"8401_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","volume":"10","author":"Y Shi","year":"2025","unstructured":"Shi Y, Han G, Zhou J, Shi X, Jia W, Cheng Y, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2025;10:658\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8401_CR5","doi-asserted-by":"crossref","unstructured":"Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. Lancet Oncol. 2025;23:220\u201333.","DOI":"10.1016\/S1470-2045(21)00650-1"},{"key":"8401_CR6","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre CA, et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 2023;13:2448\u201369.","journal-title":"Cancer Discov"},{"key":"8401_CR7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309\u201337.","journal-title":"Cell"},{"key":"8401_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"8401_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43:641\u201364.","journal-title":"Cancer Cell"},{"key":"8401_CR10","doi-asserted-by":"crossref","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6:924\u201337.","DOI":"10.1038\/s43018-025-00986-3"},{"key":"8401_CR11","doi-asserted-by":"crossref","unstructured":"Cui Y, Liu J, Wang X, Wu Y, Chang Y, Hu X, et al. Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment. J Adv Res. 2025;77:721\u201332.","DOI":"10.1016\/j.jare.2025.01.021"},{"key":"8401_CR12","doi-asserted-by":"crossref","unstructured":"Zhou Y, Wang J, Chen Y, Lin W, Zhou R, Zhao L, et al. NRIR promotes immune escape in hepatocellular cancer by regulating IFNgamma-induced PD-L1 expression. J Adv Res. 2025;78:423\u201334.","DOI":"10.1016\/j.jare.2025.02.034"},{"key":"8401_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq7019","volume":"14","author":"B Theivanthiran","year":"2022","unstructured":"Theivanthiran B, Yarla N, Haykal T, Nguyen YV, Cao L, Ferreira M, et al. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy. Sci Transl Med. 2022;14:eabq7019.","journal-title":"Sci Transl Med"},{"key":"8401_CR14","doi-asserted-by":"crossref","unstructured":"Lim JX, McTaggart T, Jung SK, Smith KJ, Hulme G, Laba S, et al. PD-1 receptor deficiency enhances CD30(+) T(reg) cell function in melanoma. Nat Immunol. 2025;26:1074\u201386.","DOI":"10.1038\/s41590-025-02172-0"},{"key":"8401_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.immuni.2025.05.006","volume":"58","author":"ZY Liu","year":"2025","unstructured":"Liu ZY, Wu CY, Wu RQ, Wang JC, Huang CX, Wang XY, et al. Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity. 2025;58:1572\u201385.e1510.","journal-title":"Immunity"},{"key":"8401_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.immuni.2022.11.014","volume":"56","author":"RQ Wu","year":"2023","unstructured":"Wu RQ, Lao XM, Chen DP, Qin H, Mu M, Cao WJ, et al. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity. 2023;56:180\u201392.e111.","journal-title":"Immunity"},{"key":"8401_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"8401_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. 2024;21:147\u201364.","journal-title":"Nat Rev Clin Oncol"},{"key":"8401_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2159-8290.CD-23-0762","volume":"14","author":"L Monteran","year":"2024","unstructured":"Monteran L, Ershaid N, Scharff Y, Zoabi Y, Sanalla T, Ding Y, et al. Combining TIGIT blockade with MDSC inhibition hinders breast cancer bone metastasis by activating antitumor immunity. Cancer Discov. 2024;14:1252\u201375.","journal-title":"Cancer Discov"},{"key":"8401_CR20","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.immuni.2025.04.027","volume":"58","author":"AG Blidner","year":"2025","unstructured":"Blidner AG, Bach CA, Garc\u00eda PA, Merlo JP, Cagnoni AJ, Bannoud N, et al. Glycosylation-driven programs coordinate immunoregulatory and pro-angiogenic functions of myeloid-derived suppressor cells. Immunity. 2025;58:1553\u201371.e1558.","journal-title":"Immunity"},{"key":"8401_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621:830\u20139.","journal-title":"Nature"},{"key":"8401_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","volume":"15","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E, et al. Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med. 2023;15:eabn6758.","journal-title":"Sci Transl Med"},{"key":"8401_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","volume":"26","author":"J He","year":"2025","unstructured":"He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, et al. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. Nat Immunol. 2025;26:391\u2013403.","journal-title":"Nat Immunol"},{"key":"8401_CR24","doi-asserted-by":"crossref","unstructured":"Bitsch R, Kurzay A, Ozbay Kurt F, De La Torre C, Lasser S, Lepper A, et al. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer. 2022;10:e004384.","DOI":"10.1136\/jitc-2021-004384"},{"key":"8401_CR25","doi-asserted-by":"crossref","unstructured":"Ghosh S, O\u2019Hara MP, Sinha P, Mazumdar T, Yapindi L, Sastry JK, et al. Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers. J Immunother Cancer. 2025;13:e009316.","DOI":"10.1136\/jitc-2024-009316"},{"key":"8401_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06524-w","volume":"15","author":"N Mukherjee","year":"2024","unstructured":"Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, et al. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. 2024;15:198.","journal-title":"Cell Death Dis"},{"key":"8401_CR27","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1158\/0008-5472.CAN-14-1482","volume":"74","author":"EK Kim","year":"2014","unstructured":"Kim EK, Jeon I, Seo H, Park YJ, Song B, Lee KA, et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 2014;74:6705\u201316.","journal-title":"Cancer Res"},{"key":"8401_CR28","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018;128:3425\u201338.","journal-title":"J Clin Invest"},{"key":"8401_CR29","doi-asserted-by":"crossref","unstructured":"Liu M, Wu C, Luo S, Hua Q, Chen HT, Weng Y, et al. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J Exp Med. 2022;219:e20211498.","DOI":"10.1084\/jem.20211498"},{"key":"8401_CR30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41556-023-01291-w","volume":"25","author":"Y Gerber-Ferder","year":"2023","unstructured":"Gerber-Ferder Y, Cosgrove J, Duperray-Susini A, Missolo-Koussou Y, Dubois M, Stepaniuk K, et al. Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche. Nat Cell Biol. 2023;25:1736\u201345.","journal-title":"Nat Cell Biol"},{"key":"8401_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn0327","volume":"386","author":"MD Park","year":"2024","unstructured":"Park MD, Le Berichel J, Hamon P, Wilk CM, Belabed M, Yatim N, et al. Hematopoietic aging promotes cancer by fueling IL-1\u03b1-driven emergency myelopoiesis. Science. 2024;386:eadn0327.","journal-title":"Science"},{"key":"8401_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1126\/science.abj2674","volume":"377","author":"Y Xu","year":"2022","unstructured":"Xu Y, Yan J, Tao Y, Qian X, Zhang C, Yin L, et al. Pituitary hormone \u03b1-MSH promotes tumor-induced myelopoiesis and immunosuppression. Science. 2022;377:1085\u201391.","journal-title":"Science"},{"key":"8401_CR33","doi-asserted-by":"crossref","unstructured":"Wu WC, Sun HW, Chen HT, Liang J, Yu XJ, Wu C, et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci USA. 2014;111:4221\u20136.","DOI":"10.1073\/pnas.1320753111"},{"key":"8401_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.immuni.2020.03.004","volume":"52","author":"E Mohamed","year":"2020","unstructured":"Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity. 2020;52:668\u201382.e667.","journal-title":"Immunity"},{"key":"8401_CR35","doi-asserted-by":"crossref","unstructured":"Tcyganov EN, Hanabuchi S, Hashimoto A, Campbell D, Kar G, Slidel TW, et al. Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. J Clin Invest. 2021;131:e145971.","DOI":"10.1172\/JCI145971"},{"key":"8401_CR36","doi-asserted-by":"crossref","unstructured":"Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1:aaf8943.","DOI":"10.1126\/sciimmunol.aaf8943"},{"key":"8401_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2014.08.015","volume":"41","author":"PT Thevenot","year":"2014","unstructured":"Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41:389\u2013401.","journal-title":"Immunity"},{"key":"8401_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.616367","volume":"11","author":"HW Sun","year":"2020","unstructured":"Sun HW, Wu WC, Chen HT, Xu YT, Yang YY, Chen J, et al. Glutamine deprivation promotes the generation and mobilization of MDSCs by enhancing expression of G-CSF and GM-CSF. Front Immunol. 2020;11:616367.","journal-title":"Front Immunol"},{"key":"8401_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cell.2014.07.002","volume":"158","author":"R Ghosh","year":"2014","unstructured":"Ghosh R, Wang L, Wang ES, Perera BG, Igbaria A, Morita S, et al. Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell. 2014;158:534\u201348.","journal-title":"Cell"},{"key":"8401_CR40","doi-asserted-by":"publisher","first-page":"e0158392","DOI":"10.1371\/journal.pone.0158392","volume":"11","author":"C Giallongo","year":"2016","unstructured":"Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, et al. Mesenchymal stem cells (MSC) regulate activation of granulocyte-like myeloid derived suppressor cells (G-MDSC) in chronic myeloid leukemia patients. PLoS One. 2016;11:e0158392.","journal-title":"PLoS One"},{"key":"8401_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s11658-025-00712-y","volume":"30","author":"C Wang","year":"2025","unstructured":"Wang C, Ju C, Du D, Zhu P, Yin J, Jia J, et al. CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1. Cell Mol Biol Lett. 2025;30:37.","journal-title":"Cell Mol Biol Lett"},{"key":"8401_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s11658-024-00637-y","volume":"29","author":"L Martinkova","year":"2024","unstructured":"Martinkova L, Zatloukalova P, Kucerikova M, Friedlova N, Tylichova Z, Zavadil-Kokas F, et al. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1\/SOX10 regulatory axis. Cell Mol Biol Lett. 2024;29:117.","journal-title":"Cell Mol Biol Lett"},{"key":"8401_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s11658-023-00461-w","volume":"28","author":"LS Cheng","year":"2023","unstructured":"Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, et al. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell Mol Biol Lett. 2023;28:47.","journal-title":"Cell Mol Biol Lett"},{"key":"8401_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s11658-023-00471-8","volume":"28","author":"X Shen","year":"2023","unstructured":"Shen X, Jin X, Fang S, Chen J. EFEMP2 upregulates PD-L1 expression via EGFR\/ERK1\/2\/c-Jun signaling to promote the invasion of ovarian cancer cells. Cell Mol Biol Lett. 2023;28:53.","journal-title":"Cell Mol Biol Lett"},{"key":"8401_CR45","doi-asserted-by":"crossref","unstructured":"Colligan SH, Amitrano AM, Zollo RA, Peresie J, Kramer ED, Morreale B, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022;132:e158661.","DOI":"10.1172\/JCI158661"},{"key":"8401_CR46","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.cmet.2022.10.010","volume":"34","author":"Z Yang","year":"2022","unstructured":"Yang Z, Huo Y, Zhou S, Guo J, Ma X, Li T, et al. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. Cell Metab. 2022;34:2018\u201335.e2018.","journal-title":"Cell Metab"},{"key":"8401_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.29847","volume":"68","author":"C Lebeaupin","year":"2018","unstructured":"Lebeaupin C, Vallee D, Rousseau D, Patouraux S, Bonnafous S, Adam G, et al. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. Hepatology. 2018;68:515\u201332.","journal-title":"Hepatology"},{"key":"8401_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08152-3","volume":"10","author":"X Sheng","year":"2019","unstructured":"Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, et al. IRE1alpha-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019;10:323.","journal-title":"Nat Commun"},{"key":"8401_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2020.02.007","volume":"476","author":"Q Gao","year":"2020","unstructured":"Gao Q, Li XX, Xu YM, Zhang JZ, Rong SD, Qin YQ, et al. IRE1alpha-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67\u201374.","journal-title":"Cancer Lett"},{"key":"8401_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41418-025-01443-5","volume":"32","author":"X Wang","year":"2025","unstructured":"Wang X, Wang Q, Wang H, Cai G, An Y, Liu P, et al. Small protein ERSP encoded by LINC02870 promotes triple negative breast cancer progression via IRE1alpha\/XBP1s activation. Cell Death Differ. 2025;32:1014\u201325.","journal-title":"Cell Death Differ"},{"key":"8401_CR51","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Y, Zhao G, Tanner EJ, Adli M, Matei D. FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. J Clin Invest. 2022;132:e151591.","DOI":"10.1172\/JCI151591"},{"key":"8401_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48330-0","volume":"15","author":"D Jiang","year":"2024","unstructured":"Jiang D, Guo Y, Wang T, Wang L, Yan Y, Xia L, et al. IRE1alpha determines ferroptosis sensitivity through regulation of glutathione synthesis. Nat Commun. 2024;15:4114.","journal-title":"Nat Commun"},{"key":"8401_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023;381:eabn4180.","journal-title":"Science"},{"key":"8401_CR54","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1016\/j.cell.2024.09.032","volume":"187","author":"L Xu","year":"2024","unstructured":"Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al. IRE1alpha silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024;187:7248\u201366.e7234.","journal-title":"Cell"},{"key":"8401_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1523-3","volume":"10","author":"M Mahameed","year":"2019","unstructured":"Mahameed M, Wilhelm T, Darawshi O, Obiedat A, Tommy WS, Chintha C, et al. The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. 2019;10:300.","journal-title":"Cell Death Dis"},{"key":"8401_CR56","doi-asserted-by":"crossref","unstructured":"Wan Y, Wang J, Chen M, Wang J, Nan F, Huang H, et al. Dual roles of IRE1alpha inhibition in reversing mitochondrial ROS-induced CD8(+) T-cell senescence and exerting direct antitumor effects in multiple myeloma. J Immunother Cancer. 2025;13:e011044.","DOI":"10.1136\/jitc-2024-011044"},{"key":"8401_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-018-0597-x","volume":"562","author":"M Song","year":"2018","unstructured":"Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, et al. IRE1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018;562:423\u20138.","journal-title":"Nature"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08401-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:05:48Z","timestamp":1769785548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08401-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8401"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08401-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7263160\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed in accordance with the guidance and approved by the Experimental Animal Ethics Committee of Zhuhai People\u2019s Hospital (No. 20250222-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"149"}}